COMPOSITION OF PIPERAZINE COMPOUND AND PD-1 INHIBITOR OR PD-L1 INHIBITOR AND USE THEREOF IN TREATING TUMORS

Title:

COMPOSITION OF PIPERAZINE COMPOUND AND PD-1 INHIBITOR OR PD-L1 INHIBITOR AND USE THEREOF IN TREATING TUMORS

Document Type and Number:

WIPO Patent Application WO/2024/032410

Kind Code:

A1

Abstract:

The present application relates to a combination of a piperazine compound and a PD-1 inhibitor antibody or a PD-L1 inhibitor antibody and use thereof in treating tumors.

More Like This:

WO/2023/232776	HALOINDOLE MACROCYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER
WO2004076461	PORPHYRIN DERIVATIVES
JPS5959692	BENZIMIDAZOTHIAZINOPERINONE COMPOUND AND SENSITIZED MATERIAL FOR ELECTROPHOTOGRAPHY HAVING PHOTOSENSITIVE LAYER CONTAINING IT

Inventors:

ZHU YUQIN (CN)
WEI YONGGANG (CN)
CHU HONGZHU (CN)
YE FEI (CN)
SU GUIZHUAN (CN)
SUN YI (CN)

Application Number:

PCT/CN2023/110231

Publication Date:

February 15, 2024

Filing Date:

July 31, 2023

Export Citation:

Click for automatic bibliography generation Help

Assignee:

CHENGDU BAIYU PHARMACEUTICAL CO LTD (CN)

International Classes:

C07D513/22; A61K31/495; A61K39/395; A61P35/00; C07D401/14; C07D403/12

Foreign References:

CN112424188A	2021-02-26
US20180318295A1	2018-11-08
EP3919079A1	2021-12-08
US20120219568A1	2012-08-30

Other References:

CHUNWAN LU, AMY V. PASCHALL, HUIDONG SHI, NATASHA SAVAGE, JENNIFER L. WALLER, MARIA E. SABBATINI, NICHOLAS H. OBERLIES, CEDRIC PEA: "The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion", JOURNAL OF THE NATIONAL CANCER INSTITUTE, OXFORD UNIVERSITY PRESS, GB, vol. 109, no. 6, 28 January 2017 (2017-01-28), GB , pages djw283, XP055429970, ISSN: 0027-8874, DOI: 10.1093/jnci/djw283

Attorney, Agent or Firm:

BEIJING SANYOU INTELLECTUAL PROPERTY AGENCY LTD. (CN)

Download PDF:

View/Download PDF PDF Help

Previous Patent: USE OF PIPERAZINE COMPOUND IN COMBINATION WITH RADIOTHERAPY FOR TREATMENT OF TUMOR

Next Patent: POWER AMPLIFIER AND CONTROL METHOD THEREFOR, AND COMMUNICATION DEVICE